These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31775072)

  • 1. Cellular uptake of protic ruthenium complexes is influenced by pH dependent passive diffusion and energy dependent efflux.
    Park S; Gray JL; Altman SD; Hairston AR; Beswick BT; Kim Y; Papish ET
    J Inorg Biochem; 2020 Feb; 203():110922. PubMed ID: 31775072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
    Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET
    Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Singlet Oxygen Formation vs Photodissociation for Light-Responsive Protic Ruthenium Anticancer Compounds: The Oxygenated Substituent Determines Which Pathway Dominates.
    Qu F; Lamb RW; Cameron CG; Park S; Oladipupo O; Gray JL; Xu Y; Cole HD; Bonizzoni M; Kim Y; McFarland SA; Webster CE; Papish ET
    Inorg Chem; 2021 Feb; 60(4):2138-2148. PubMed ID: 33534562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium Complexes with Protic Ligands: Influence of the Position of OH Groups and π Expansion on Luminescence and Photocytotoxicity.
    Oladipupo OE; Prescott MC; Blevins ER; Gray JL; Cameron CG; Qu F; Ward NA; Pierce AL; Collinson ER; Hall JF; Park S; Kim Y; McFarland SA; Fedin I; Papish ET
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release.
    Hufziger KT; Thowfeik FS; Charboneau DJ; Nieto I; Dougherty WG; Kassel WS; Dudley TJ; Merino EJ; Papish ET; Paul JJ
    J Inorg Biochem; 2014 Jan; 130():103-11. PubMed ID: 24184694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.
    Chen Y; Qin MY; Wu JH; Wang L; Chao H; Ji LN; Xu AL
    Eur J Med Chem; 2013; 70():120-9. PubMed ID: 24141202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonyl-heterobimetallic Ru(II)/Fe(II)-complexes containing polypyridyl ligands: Synthesis, characterization, cellular viability assays and interactions with biomolecules.
    Dávila-Rodríguez MJ; Barolli JP; de Oliveira KM; Colina-Vegas L; da Silva Miranda F; Castellano EE; Von Poelhsitz G; Batista AA
    Arch Biochem Biophys; 2018 Dec; 660():156-167. PubMed ID: 30389443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.
    Oladipupo OE; Brown SR; Lamb RW; Gray JL; Cameron CG; DeRegnaucourt AR; Ward NA; Hall JF; Xu Y; Petersen CM; Qu F; Shrestha AB; Thompson MK; Bonizzoni M; Webster CE; McFarland SA; Kim Y; Papish ET
    Photochem Photobiol; 2022 Jan; 98(1):102-116. PubMed ID: 34411308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, spectroscopic characterization, photochemical and photophysical properties and biological activities of ruthenium complexes with mono- and bi-dentate histamine ligand.
    Cardoso CR; de Aguiar I; Camilo MR; Lima MV; Ito AS; Baptista MS; Pavani C; Venâncio T; Carlos RM
    Dalton Trans; 2012 Jun; 41(22):6726-34. PubMed ID: 22539182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer activity of ruthenium(II) arene complexes bearing 1,2,3,4-tetrahydroisoquinoline amino alcohol ligands.
    Chelopo MP; Pawar SA; Sokhela MK; Govender T; Kruger HG; Maguire GE
    Eur J Med Chem; 2013 Aug; 66():407-14. PubMed ID: 23827181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amberlite IR-120 (H) mediated "on water" synthesis of fluorescent Ruthenium(II)-arene 8-hydroxyquinoline complexes for cancer therapy and live cell imaging.
    Mondal A; De S; Maiti S; Sarkar B; Sk AK; Jacob R; Moorthy A; Paira P
    J Photochem Photobiol B; 2018 Jan; 178():380-394. PubMed ID: 29195215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruthenium(II) polypyridyl complexes: synthesis and studies of DNA binding, photocleavage, cytotoxicity, apoptosis, cellular uptake, and antioxidant activity.
    Liu YJ; Liang ZH; Li ZZ; Yao JH; Huang HL
    DNA Cell Biol; 2011 Oct; 30(10):829-38. PubMed ID: 21395447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxicity, apoptosis, cellular uptake, cell cycle arrest, photocleavage, and antioxidant activity of 1, 10-phenanthroline ruthenium(II) complexes.
    Liu YJ; Li ZZ; Liang ZH; Yao JH; Huang HL
    DNA Cell Biol; 2011 Oct; 30(10):839-48. PubMed ID: 21568758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organometallic ruthenium(II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties.
    Pernar M; Kokan Z; Kralj J; Glasovac Z; Tumir LM; Piantanida I; Eljuga D; Turel I; Brozovic A; Kirin SI
    Bioorg Chem; 2019 Jun; 87():432-446. PubMed ID: 30925428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes.
    Chen J; Peng F; Zhang Y; Li B; She J; Jie X; Zou Z; Chen M; Chen L
    Eur J Med Chem; 2017 Nov; 140():104-117. PubMed ID: 28923379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents.
    Lucas SJ; Lord RM; Wilson RL; Phillips RM; Sridharan V; McGowan PC
    Dalton Trans; 2012 Dec; 41(45):13800-2. PubMed ID: 23015068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First polymer "ruthenium-cyclopentadienyl" complex as potential anticancer agent.
    Valente A; Garcia MH; Marques F; Miao Y; Rousseau C; Zinck P
    J Inorg Biochem; 2013 Oct; 127():79-81. PubMed ID: 23896008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular "light switch" complexes.
    Shobha Devi C; Anil Kumar D; Singh SS; Gabra N; Deepika N; Kumar YP; Satyanarayana S
    Eur J Med Chem; 2013 Jun; 64():410-21. PubMed ID: 23665797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel anticancer ruthenium-arene pyridinylmethylene scaffolds via three-component reaction.
    Jadhav GR; Sinha S; Chhabra M; Paira P
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2695-700. PubMed ID: 27090558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.